CRO News
Halia Therapeutics Partners with Southern Star Research to Launch Phase 1 Trial for Neurodegenerative Drug
Halia Therapeutics, Inc. has entered a strategic collaboration with Southern Star Research Pty Ltd, an Australian contract research organisation (CRO), to launch a Phase 1 clinical trial for its LRRK2 inhibitor, HT-4253. This collaboration signifies a crucial step in the
4 September 2024